Developer docs
API playgroundTry for free, no card

Search company profiles

ARTES Biotechnology

Full company profile

uuid000n1jc

Namestring
ARTES Biotechnology
Legal namestring
ARTES Biotechnology GmbH
Company typeenum
Private
Founded yearint
2002
Descriptiontext

ARTES Biotechnology GmbH is a private German Contract Development and Manufacturing Organization (CDMO) founded in May 2002 and headquartered in Langenfeld, Germany. The company specializes in microbial cell line and process development for recombinant protein production using proprietary yeast (Hansenula polymorpha, Pichia pastoris, Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, with the Hansenula polymorpha platform capable of integrating up to 120 gene copies per cell. ARTES operates approximately 875 m² of S1 laboratory and process development facilities and employs a team of about 24 people, with a leadership team including founder Dr. Michael Piontek, Business Development Director Dr. Melanie Piontek, and Managing Director Volker Jenzelewski (appointed January 2024, prior roles at Dynavax Europe and EUFETS/BioNTech).

The company's commercial offerings span three revenue streams: (1) CDMO services covering microbial cell line development, upstream and downstream process development, non-GMP manufacturing of test and preclinical material, and VLP vaccine development using proprietary METAVAX (enveloped VLP) and SplitCore (capsid VLP) platforms; (2) technology licensing of pre-developed ready-to-use cell lines and processes for biosimilars, vaccines, and enzymes, with flexible terms including non-exclusive or exclusive, regional or global licenses; and (3) direct-to-customer sales of lab reagents (antigens, enzymes, functional proteins such as HBsAg, HPV L1 proteins, Endoglycosidase H, T7 RNA Polymerase, Human Serum Albumin, and Interferon Alpha) through an online webshop. ARTES serves pharmaceutical and biopharmaceutical companies, vaccine manufacturers, enzyme producers, cosmetics, diagnostics, and nutrition companies globally, with named engagements including Serum Institute of India (R21/Matrix-M malaria vaccine, 2024), Basic Pharma (recombinant Human Serum Albumin), Cellumed (enzymes for mRNA vaccine manufacturing), Provenance Bio (precision-fermented collagen peptides), and Burnet Institute (malaria vaccine research).

ARTES holds patents in the EU (EP3594330A1) and US (US11053478B2) for VLP purification technology, and its platforms have supported products achieving US-FDA, EMA, NRC approvals, GRAS certifications, and WHO recommendations. The company monetizes through CDMO contracts, licensing fees and royalties, and small-ticket lab reagent sales, exhibiting at major industry conferences including BIO International and BIO-Europe to drive enterprise business development.

Short descriptiontext

ARTES Biotechnology is a German CDMO founded in 2002 that develops microbial cell lines and production processes (Hansenula polymorpha yeast, E. coli) for recombinant proteins, vaccines, and biosimilars, serving pharmaceutical, biotech, cosmetics, diagnostics, and nutrition clients globally via services, licensing, and lab reagents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLangenfeld, Germany
HQ citystring
Langenfeld
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial cell line development, CDMO services, recombinant protein production, VLP vaccine platform, biopharmaceutical process development
Industry3 codes
PRIMARYHLAGABAL
Process Development & Tech Transfer Services (CDMO)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bioprocess CDMO and Microbial Expression Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services including microbial cell line development, process development, and manufacturing of high-quality test and preclinical material for vaccines, biopharmaceuticals, biosimilars, and enzymes.

artes-biotechnology.biz
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of pre-developed 'ready-to-use' production cell lines and processes for biosimilars, vaccines, enzymes, and other products. Licenses available as non-exclusive or exclusive, regional or global, with flexible payment terms including lump sum, milestone payments, and royalties.

artes-biotechnology.biz
3Lab Reagents Sales
TypeOne Time License
Description

Direct sales of recombinant protein antigens, enzymes, and functional proteins for research purposes through the company's webshop. Products manufactured using proprietary Hansenula polymorpha or E. coli expression systems.

artes-biotechnology.biz
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain, Operations
Pricing details3 tiers
1Recombinant antigens (HBsAg, HPV L1 proteins) priced 150-1800 EUR
ModelUnit PricingBilling cadencePay-as-you-go
Notes

HBsAg adw2: 150-1200 EUR; HPV L1 proteins (6, 11, 16, 18, 31, 33): 450-1800 EUR. Prices vary by quantity (100-500 µg).

artes-biotechnology.biz
2Enzymes (Endoglycosidase H, Enterokinase, Inorganic Pyrophosphatase, T7 RNA Polymerase) priced 55-400 EUR
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Endoglycosidase H: 120-240 EUR; Enterokinase: 110-400 EUR; Inorganic Pyrophosphatase: 55-220 EUR; T7 RNA Polymerase: 80-180 EUR. Prices vary by unit quantity.

artes-biotechnology.biz
3Functional proteins (Brazzein, Human Serum Albumin, Interferon Alpha 2a/2b) priced 95-4000 EUR
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Brazzein: 500-4000 EUR; Human Serum Albumin: 95-395 EUR; Interferon Alpha 2a: 185-325 EUR; Interferon Alpha 2b: 215-375 EUR. Prices vary by quantity.

artes-biotechnology.biz
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1METAVAX
Description

Platform for enveloped Virus-Like Particles (eVLPs) for development of novel nanoparticle subunit vaccines in human and animal health.

artes-biotechnology.biz
+1 more record
Core offering1 text field

ARTES Biotechnology is a Contract Development and Manufacturing Organization (CDMO) providing microbial cell line development, fermentation and downstream process development, non-GMP manufacturing of test and preclinical material, and VLP vaccine development for recombinant proteins. The company also licenses pre-developed ready-to-use production cell lines and processes for biosimilars, vaccines, and enzymes, and sells recombinant antigens, enzymes, and functional proteins as research reagents through an online webshop. Core platforms include the proprietary Hansenula polymorpha yeast expression system and the METAVAX and SplitCore VLP vaccine technologies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Cost of goods below 1 Euro per dose for VLP vaccine production
+2 more records
Product overview1 text field

ARTES Biotechnology is a CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform for recombinant protein production using microbial expression systems. The core offering consists of CDMO Services including Microbial Cell Line Development, Process Development, Manufacturing, and VLP Vaccine Development, supported by a License Offer for pre-developed processes and Technology Transfer services. The company operates proprietary technology platforms including METAVAX® (enveloped VLPs) and SplitCore/Hep-B Core (capsid VLPs). Lab Reagents product line includes research-grade antigens (HBsAg, HPV L1 proteins), enzymes (Endoglycosidase H, Enterokinase, T7 RNA Polymerase, Inorganic Pyrophosphatase), and functional proteins (Human Serum Albumin, Interferon Alpha 2A/B, Brazzein, Monellin). The company also offers vaccine products (Hepatitis B, HPV) and biosimilar processes through technology licensing.

Product and service1 record
1CDMO Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Partnership to scale Col-01, a precision-fermented hydroxylated collagen peptide for the beauty-from-within supplement market. Combines Provenance Bio's proprietary hydroxylation technology with ARTES' expertise in microbial strain engineering and bioprocess development to produce animal-free collagen alternative with superior purity and consistency.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

ARTES technology contributed to R21/Matrix-M malaria vaccine launched by Serum Institute of India in 2024. Demonstrates successful application of ARTES VLP vaccine platform in commercial product development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Strategic collaboration and co-marketing partnership for pharmaceutical recombinant protein production. Inaugural product is recombinant Human Serum Albumin (rHSA) from Hansenula polymorpha yeast. Project partially funded by BioMan4R2 project within European SMP COSME program. Collaboration aims to establish streamlined supply chain for expediting time-to-market.

4BioMan4R2
Strategic tierMinorTypeOthersAnnounced on2023-10-01
Description

European SMP COSME program project providing financial support and networking for the ARTES-Basic Pharma collaboration on recombinant Human Serum Albumin production. Focuses on EU resilience in health Biomanufacturing and MedTech areas.

artes-biotechnology.biz
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Development and License Agreement for generating microbial production cell lines, processes, and documentation for cGMP manufacturing of two enzymes required in mRNA vaccine manufacturing. ARTES develops high-yield cell lines and processes; results transferred to Richter-Helm BioLogics for cGMP production. Project management supported by Korean representative Quality by Design, Inc.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-10-01
Description

German CMO partner for cGMP manufacturing. Receives technology transfer from ARTES for production of enzymes developed for Cellumed mRNA vaccine project.

7Quality by Design, Inc.
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-10-01
Description

Korean representative providing project management support for Cellumed collaboration.

artes-biotechnology.biz
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-09-01
Description

Collaborative research on malaria vaccine candidates using VLP technology. Funded by PATH Malaria Vaccine Initiative and others. Published data on efficient production of malaria transmission-blocking vaccine candidates (Pfs25 and Pfs230) as chimeric VLPs using ARTES' METAVAX platform. Demonstrated induction of transmission-blocking antibodies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Germany-based microbial CDMO specializing in bacterial and yeast-based recombinant protein production for clinical and commercial supply. Directly comparable to ARTES as a microbial-focused CDMO in Germany; also serves as ARTES' cGMP manufacturing partner, highlighting both overlap and partnership.

TypeDirect peer
Description

Nordic CDMO offering microbial and mammalian process development, manufacturing, and aseptic fill-finish. Comparable as a mid-sized European CDMO serving biotech with similar recombinant protein and vaccine capabilities, though broader in scope (including viral vectors and cell therapy).

TypeDirect peer
Description

German-headquartered CDMO focused on recombinant protein production from microbial and mammalian expression systems. Directly comparable to ARTES in microbial CDMO services for biopharmaceuticals and biosimilars, though larger scale and broader service offering.

TypeBroad incumbent
Description

Global CDMO offering microbial, mammalian, and cell therapy services with facilities in Europe, US, and Asia. Comparable in providing microbial CDMO services for vaccines and recombinant proteins but at significantly larger scale across multiple modalities and geographies.

5Boehringer Ingelheim BioXcellence
TypeOthers
Description

Large CDMO division of Boehringer Ingelheim offering microbial (E. coli, yeast) and mammalian contract manufacturing. Comparable as a microbial CDMO serving vaccine and biopharma customers but at far greater scale, with global footprint and integrated services.

TypeBroad incumbent
Description

Commercial-stage vaccine developer using recombinant VLP technology (Matrix-M adjuvant platform). Comparable as a VLP-based vaccine player using similar virus-like particle approach; however, Novavax is product-owning and publicly traded, putting ARTES in a platform-supplier role.

TypeBroad incumbent
Description

Canadian VLP vaccine developer (acquired by Mitsubishi) using plant-based and VLP platforms for vaccines. Comparable as a VLP-vaccine technology player, though using a different production system (plants vs. microbial); both serve global vaccine markets.

TypeBroad incumbent
Description

Global CDMO leader with extensive microbial and mammalian manufacturing capabilities for biologics, vaccines, and small molecules. Comparable at the CDMO service layer, especially for microbial recombinant protein and vaccine projects, but at vastly greater scale and geographic reach.

TypeBroad incumbent
Description

Global biologics CDMO offering end-to-end microbial and mammalian services from cell line to commercial manufacturing. Comparable for recombinant protein CDMO services but with much larger headcount, global facilities, and integrated commercial-scale capacity.

TypeEmerging player
Description

Swiss bioconjugate vaccine developer (GSK-owned) using microbial expression for glycoengineered vaccines. Comparable as a microbial-expressed vaccine technology company in the European biotech ecosystem, though focused on bioconjugates rather than VLPs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARTES Biotechnology

Bioprocess CDMO and Microbial Expression Servicesartes-biotechnology.biz

ARTES Biotechnology is a German CDMO founded in 2002 that develops microbial cell lines and production processes (Hansenula polymorpha yeast, E. coli) for recombinant proteins, vaccines, and biosimilars, serving pharmaceutical, biotech, cosmetics, diagnostics, and nutrition clients globally via services, licensing, and lab reagents.

What ARTES Biotechnology does

ARTES Biotechnology GmbH is a private German Contract Development and Manufacturing Organization (CDMO) founded in May 2002 and headquartered in Langenfeld, Germany. The company specializes in microbial cell line and process development for recombinant protein production using proprietary yeast (Hansenula polymorpha, Pichia pastoris, Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, with the Hansenula polymorpha platform capable of integrating up to 120 gene copies per cell. ARTES operates approximately 875 m² of S1 laboratory and process development facilities and employs a team of about 24 people, with a leadership team including founder Dr. Michael Piontek, Business Development Director Dr. Melanie Piontek, and Managing Director Volker Jenzelewski (appointed January 2024, prior roles at Dynavax Europe and EUFETS/BioNTech).

The company's commercial offerings span three revenue streams: (1) CDMO services covering microbial cell line development, upstream and downstream process development, non-GMP manufacturing of test and preclinical material, and VLP vaccine development using proprietary METAVAX (enveloped VLP) and SplitCore (capsid VLP) platforms; (2) technology licensing of pre-developed ready-to-use cell lines and processes for biosimilars, vaccines, and enzymes, with flexible terms including non-exclusive or exclusive, regional or global licenses; and (3) direct-to-customer sales of lab reagents (antigens, enzymes, functional proteins such as HBsAg, HPV L1 proteins, Endoglycosidase H, T7 RNA Polymerase, Human Serum Albumin, and Interferon Alpha) through an online webshop. ARTES serves pharmaceutical and biopharmaceutical companies, vaccine manufacturers, enzyme producers, cosmetics, diagnostics, and nutrition companies globally, with named engagements including Serum Institute of India (R21/Matrix-M malaria vaccine, 2024), Basic Pharma (recombinant Human Serum Albumin), Cellumed (enzymes for mRNA vaccine manufacturing), Provenance Bio (precision-fermented collagen peptides), and Burnet Institute (malaria vaccine research).

ARTES holds patents in the EU (EP3594330A1) and US (US11053478B2) for VLP purification technology, and its platforms have supported products achieving US-FDA, EMA, NRC approvals, GRAS certifications, and WHO recommendations. The company monetizes through CDMO contracts, licensing fees and royalties, and small-ticket lab reagent sales, exhibiting at major industry conferences including BIO International and BIO-Europe to drive enterprise business development.

ARTES Biotechnology firmographics

Firmographics
Name
ARTES Biotechnology
Legal name
ARTES Biotechnology GmbH
Website
https://artes-biotechnology.biz
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
ARTES Biotechnology is a German CDMO founded in 2002 that develops microbial cell lines and production processes (Hansenula polymorpha yeast, E. coli) for recombinant proteins, vaccines, and biosimilars, serving pharmaceutical, biotech, cosmetics, diagnostics, and nutrition clients globally via services, licensing, and lab reagents.
Ownership category
akta.pro rank

ARTES Biotechnology industry classification

Industry
Product category
Bioprocess CDMO and Microbial Expression Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAL
Process Development & Tech Transfer Services (CDMO)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Microbial cell line development
  • CDMO services
  • Recombinant protein production
  • VLP vaccine platform
  • Biopharmaceutical process development

Where ARTES Biotechnology is headquartered

Location

Headquarters

HQ city
Langenfeld
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

ARTES Biotechnology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. CDMO Services: Contract Development and Manufacturing Organization services including microbial cell line development, process development, and manufacturing of high-quality test and preclinical material for vaccines, biopharmaceuticals, biosimilars, and enzymes.
  2. Technology Licensing: Licensing of pre-developed 'ready-to-use' production cell lines and processes for biosimilars, vaccines, enzymes, and other products. Licenses available as non-exclusive or exclusive, regional or global, with flexible payment terms including lump sum, milestone payments, and royalties.
  3. Lab Reagents Sales: Direct sales of recombinant protein antigens, enzymes, and functional proteins for research purposes through the company's webshop. Products manufactured using proprietary Hansenula polymorpha or E. coli expression systems.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRecombinant antigens (HBsAg, HPV L1 proteins) priced 150-1800 EUR
Unit PricingPay-as-you-goEnzymes (Endoglycosidase H, Enterokinase, Inorganic Pyrophosphatase, T7 RNA Polymerase) priced 55-400 EUR
Unit PricingPay-as-you-goFunctional proteins (Brazzein, Human Serum Albumin, Interferon Alpha 2a/2b) priced 95-4000 EUR

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

ARTES Biotechnology product offering

Product offering

Core offering

ARTES Biotechnology is a Contract Development and Manufacturing Organization (CDMO) providing microbial cell line development, fermentation and downstream process development, non-GMP manufacturing of test and preclinical material, and VLP vaccine development for recombinant proteins. The company also licenses pre-developed ready-to-use production cell lines and processes for biosimilars, vaccines, and enzymes, and sells recombinant antigens, enzymes, and functional proteins as research reagents through an online webshop. Core platforms include the proprietary Hansenula polymorpha yeast expression system and the METAVAX and SplitCore VLP vaccine technologies.

Product overview

ARTES Biotechnology is a CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform for recombinant protein production using microbial expression systems. The core offering consists of CDMO Services including Microbial Cell Line Development, Process Development, Manufacturing, and VLP Vaccine Development, supported by a License Offer for pre-developed processes and Technology Transfer services. The company operates proprietary technology platforms including METAVAX® (enveloped VLPs) and SplitCore/Hep-B Core (capsid VLPs). Lab Reagents product line includes research-grade antigens (HBsAg, HPV L1 proteins), enzymes (Endoglycosidase H, Enterokinase, T7 RNA Polymerase, Inorganic Pyrophosphatase), and functional proteins (Human Serum Albumin, Interferon Alpha 2A/B, Brazzein, Monellin). The company also offers vaccine products (Hepatitis B, HPV) and biosimilar processes through technology licensing.

Differentiator

Problem solved

Functional benefit

Brands

  • METAVAX: Platform for enveloped Virus-Like Particles (eVLPs) for development of novel nanoparticle subunit vaccines in human and animal health.
  • SplitCore

Products and services

  • CDMO Services

Quantifiable outcome

  • Cost of goods below 1 Euro per dose for VLP vaccine production
  • +2 more outcomes

Companies that use ARTES Biotechnology

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles4 records

ARTES Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ARTES Biotechnology partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Provenance BiocoreStrategic or Co-development Partner · 12 March 2026Partnership to scale Col-01, a precision-fermented hydroxylated collagen peptide for the beauty-from-within supplement market. Combines Provenance Bio's proprietary hydroxylation technology with ARTES' expertise in microbial strain engineering and bioprocess development to produce animal-free collagen alternative with superior purity and consistency.
  • Serum Institute of IndiacoreTechnology or Integration · 1 January 2024ARTES technology contributed to R21/Matrix-M malaria vaccine launched by Serum Institute of India in 2024. Demonstrates successful application of ARTES VLP vaccine platform in commercial product development.
  • Basic PharmacoreStrategic or Co-development Partner · 1 October 2023Strategic collaboration and co-marketing partnership for pharmaceutical recombinant protein production. Inaugural product is recombinant Human Serum Albumin (rHSA) from Hansenula polymorpha yeast. Project partially funded by BioMan4R2 project within European SMP COSME program. Collaboration aims to establish streamlined supply chain for expediting time-to-market.
  • BioMan4R2minorOthers · 1 October 2023European SMP COSME program project providing financial support and networking for the ARTES-Basic Pharma collaboration on recombinant Human Serum Albumin production. Focuses on EU resilience in health Biomanufacturing and MedTech areas.
  • Cellumed Co. Ltd.coreStrategic or Co-development Partner · 1 October 2021Development and License Agreement for generating microbial production cell lines, processes, and documentation for cGMP manufacturing of two enzymes required in mRNA vaccine manufacturing. ARTES develops high-yield cell lines and processes; results transferred to Richter-Helm BioLogics for cGMP production. Project management supported by Korean representative Quality by Design, Inc.
  • Richter-Helm BioLogics GmbH & Co. KGminorImplementation/ SI/ Consulting Partner · 1 October 2021German CMO partner for cGMP manufacturing. Receives technology transfer from ARTES for production of enzymes developed for Cellumed mRNA vaccine project.
  • Quality by Design, Inc.minorImplementation/ SI/ Consulting Partner · 1 October 2021Korean representative providing project management support for Cellumed collaboration.
  • Burnet InstitutecoreStrategic or Co-development Partner · 1 September 2014Collaborative research on malaria vaccine candidates using VLP technology. Funded by PATH Malaria Vaccine Initiative and others. Published data on efficient production of malaria transmission-blocking vaccine candidates (Pfs25 and Pfs230) as chimeric VLPs using ARTES' METAVAX platform. Demonstrated induction of transmission-blocking antibodies.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

ARTES Biotechnology competitors and assessment

Company assessment

Direct peers

  • Richter-Helm BioLogics: Germany-based microbial CDMO specializing in bacterial and yeast-based recombinant protein production for clinical and commercial supply. Directly comparable to ARTES as a microbial-focused CDMO in Germany; also serves as ARTES' cGMP manufacturing partner, highlighting both overlap and partnership.
  • Biovian: Nordic CDMO offering microbial and mammalian process development, manufacturing, and aseptic fill-finish. Comparable as a mid-sized European CDMO serving biotech with similar recombinant protein and vaccine capabilities, though broader in scope (including viral vectors and cell therapy).
  • Rentschler Biopharma: German-headquartered CDMO focused on recombinant protein production from microbial and mammalian expression systems. Directly comparable to ARTES in microbial CDMO services for biopharmaceuticals and biosimilars, though larger scale and broader service offering.

Broad incumbents

  • AGC Biologics: Global CDMO offering microbial, mammalian, and cell therapy services with facilities in Europe, US, and Asia. Comparable in providing microbial CDMO services for vaccines and recombinant proteins but at significantly larger scale across multiple modalities and geographies.
  • Novavax: Commercial-stage vaccine developer using recombinant VLP technology (Matrix-M adjuvant platform). Comparable as a VLP-based vaccine player using similar virus-like particle approach; however, Novavax is product-owning and publicly traded, putting ARTES in a platform-supplier role.
  • Medicago (Mitsubishi): Canadian VLP vaccine developer (acquired by Mitsubishi) using plant-based and VLP platforms for vaccines. Comparable as a VLP-vaccine technology player, though using a different production system (plants vs. microbial); both serve global vaccine markets.
  • Lonza: Global CDMO leader with extensive microbial and mammalian manufacturing capabilities for biologics, vaccines, and small molecules. Comparable at the CDMO service layer, especially for microbial recombinant protein and vaccine projects, but at vastly greater scale and geographic reach.
  • WuXi Biologics: Global biologics CDMO offering end-to-end microbial and mammalian services from cell line to commercial manufacturing. Comparable for recombinant protein CDMO services but with much larger headcount, global facilities, and integrated commercial-scale capacity.

Others

  • Boehringer Ingelheim BioXcellence: Large CDMO division of Boehringer Ingelheim offering microbial (E. coli, yeast) and mammalian contract manufacturing. Comparable as a microbial CDMO serving vaccine and biopharma customers but at far greater scale, with global footprint and integrated services.

Emerging players

  • GlycoVaxyn: Swiss bioconjugate vaccine developer (GSK-owned) using microbial expression for glycoengineered vaccines. Comparable as a microbial-expressed vaccine technology company in the European biotech ecosystem, though focused on bioconjugates rather than VLPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ARTES Biotechnology social profiles

Digital presence

ARTES Biotechnology compliance and trust

Trust signal

Compliance5 records

ARTES Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARTES Biotechnology leadership team

Management profile

Number of profiles

Profiles5 records

ARTES Biotechnology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARTES Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARTES Biotechnology

What does ARTES Biotechnology do?

ARTES Biotechnology is a Contract Development and Manufacturing Organization (CDMO) providing microbial cell line development, fermentation and downstream process development, non-GMP manufacturing of test and preclinical material, and VLP vaccine development for recombinant proteins. The company also licenses pre-developed ready-to-use production cell lines and processes for biosimilars, vaccines, and enzymes, and sells recombinant antigens, enzymes, and functional proteins as research reagents through an online webshop. Core platforms include the proprietary Hansenula polymorpha yeast expression system and the METAVAX and SplitCore VLP vaccine technologies.

Is ARTES Biotechnology a public or private company?

ARTES Biotechnology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ARTES Biotechnology founded?

ARTES Biotechnology was founded in 2002. It employs 1 to 10 people.

Where is ARTES Biotechnology based?

ARTES Biotechnology is headquartered in Langenfeld, Germany, in the Europe region.

How does ARTES Biotechnology make money?

Three revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing and lab Reagents Sales.

Who are ARTES Biotechnology's main competitors?

Direct peers on record are Richter-Helm BioLogics, Biovian and Rentschler Biopharma. Broad incumbents are AGC Biologics, Novavax, Medicago (Mitsubishi), Lonza and WuXi Biologics. Boehringer Ingelheim BioXcellence is listed as an others. GlycoVaxyn is listed as an emerging player.

Does ARTES Biotechnology have an API?

No public API is recorded for ARTES Biotechnology.

What industry is ARTES Biotechnology in?

ARTES Biotechnology's product category is Bioprocess CDMO and Microbial Expression Services. Its primary akta.pro industry code is HLAGABAL, Process Development & Tech Transfer Services (CDMO), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
nutraingredients.comAcross the Nutraverse: Human milk analytics hub, precision fermented collagen, pharmacovigilance for natural productsThree separate developments in the nutraceutical and health ingredients sector were reported this week. The Human Milk Institute at UC San Diego launched the Milk Analytics Core, a first-of-its-kind analytical hub to investigate bioactive molecules in human milk for therapeutic discovery and ingredient innovation. Provenance Bio partnered with German CDMO Artes Biotechnology to scale its precision hydroxylated collagen peptide Col-01, using microbial expression systems to produce a consistent, animal-free collagen alternative. Additionally, a global survey led by Professor Jo Barnes from the University of Auckland will assess pharmacovigilance practices across the natural health products sector, targeting over 200 organizations and regulatory bodies worldwide.nutraingredients.comProtein startup partners global tech specialist to scale ‘superior’ animal-free collagenProvenance Bio, a U.S.-based biotech startup, has partnered with German biotech firm Artes Biotechnology to develop and scale Col-01, an animal-free collagen produced through precision fermentation. The companies claim this collagen offers superior purity and consistency compared to traditional animal-derived collagen, eliminating risks of supply chain contaminants and batch variability. The global collagen supplements market was valued at $5.84 billion in 2025 and is projected to reach $13.92 billion by 2034, driving demand for sustainable alternatives.EIN PresswireAlbumin Excipient Market Drivers 2025-2029: Regional Outlook and Sizing AnalysisThe global albumin excipient market is projected to grow from $4.85 billion in 2024 to $6.64 billion by 2029, driven by expansion in the biopharmaceutical sector, rising chronic diseases, and increased drug development investments. Key trends include biodegradable solutions, strategic partnerships, and customized albumin products. In October 2023, Germany's ARTES Biotechnology GmbH partnered with the Netherlands' Basic Pharma to advance recombinant protein production and optimize supply chains.